At present, it would be prudent to consider an HbA1c target of 58 mmol/mol (7.5%) for most people with CKD if their glucose-lowering therapies include insulin and a target of up to 68 mmol/mol (8.5%) in frail people with more advanced CKD (stage 4 and above). This evidence concerns the gene INS and chronic kidney disease.